Shanghai RAAS continues share repurchase program

Shanghai RAAS Blood Products (SZSE:002252) announced continued progress in its share repurchase program, intended for employee stock ownership or equity incentive plans. As of April 30, 2025, the company had cumulatively repurchased 39,129,851 shares, representing 0.59% of the total share capital, at prices ranging from CNY 6.62 to CNY 7.09 per share, for a total cost of CNY 267,757,701.19 (excluding transaction costs). By May 7, 2025, this number increased to 46,729,752 shares, or 0.70% of the total share capital, with prices in the same range and a total cost of CNY 319,560,846.98 (excluding transaction costs). The repurchases comply with the company's established repurchase plan and relevant laws and regulations, and the company will continue to implement the repurchase plan, with updates to be provided according to applicable regulations.